Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Aisling Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Aisling Capital

Aisling Capital

Operating

Aisling Capital: Investing in healthcare innovations for disease diagnosis, prevention, and treatment.

Location
New York City, NY, US
Founded
2000
Firm
Compare
Portfolio
Employees
Website

Aisling Capital is an investment firm focused on health-related innovations, particularly in biotechnology and biopharmaceuticals. The firm typically invests in Series A to Series E rounds, with a strong emphasis on later-stage investments such as Series B and Series C. Aisling Capital targets companies developing novel therapeutics for disease diagnosis, prevention, and treatment, leveraging advancements in genomics and biotechnology.

Notable portfolio companies include BridgeBio Pharma, Biohaven Pharmaceuticals, and Loxo Oncology. Key partners at Aisling Capital bring extensive experience from leading institutions in the healthcare sector. The firm's investment philosophy centers on backing transformative healthcare innovations with the potential to address significant unmet medical needs. Aisling Capital offers value-add services such as strategic guidance, operational support, and access to a robust network of industry experts to help portfolio companies achieve their growth objectives.

Aisling Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments59
Current Portfolio Count28
Total Portfolio Exits7

Top Investment Stages

Series C16 (31.4%)
Series B14 (27.5%)
Series Unknown9 (17.6%)
Post Ipo Equity6 (11.8%)
Series A6 (11.8%)

Stage Mix

Series C 31%Series B 27%Series Unknown 18%Post Ipo Equity 12%Series A 12%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Bicara Therapeutics logo

Bicara Therapeutics

Garuda Therapeutics logo

Garuda Therapeutics

Forge Biologics logo

Forge Biologics

Dren Bio logo

Dren Bio

Antios Therapeutics logo

Antios Therapeutics

Wugen logo

Wugen

Spruce Biosciences logo

Spruce Biosciences

Ajax Health logo

Ajax Health

Poseida Therapeutics logo

Poseida Therapeutics

BridgeBio Pharma logo

BridgeBio Pharma

Earlens logo

Earlens

Zosano Pharma logo

Zosano Pharma

Arcus Biosciences logo

Arcus Biosciences

Vyne Therapeutics logo

Vyne Therapeutics

Promentis Pharmaceuticals logo

Promentis Pharmaceuticals

Bristol Myers Squibb logo

Bristol Myers Squibb

Prolacta Bioscience logo

Prolacta Bioscience

Biohaven logo

Biohaven

Aclaris Therapeutics logo

Aclaris Therapeutics

Syros Pharmaceuticals logo

Syros Pharmaceuticals

ViewRay logo

ViewRay

Cidara Therapeutics logo

Cidara Therapeutics

Agile Therapeutics logo

Agile Therapeutics

Loxo Oncology logo

Loxo Oncology

Tria Beauty logo

Tria Beauty

Aisling Capital - Classification

Also Known As
  • Aisling Capital Management LP
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end